Literature DB >> 27882479

Albendazole Microcrystal Formulations Based on Chitosan and Cellulose Derivatives: Physicochemical Characterization and In Vitro Parasiticidal Activity in Trichinella spiralis Adult Worms.

Josefina Priotti1, Ana V Codina2, Darío Leonardi1,3, María D Vasconi2,4, Lucila I Hinrichsen5,6, María C Lamas7,8,9.   

Abstract

The oral route has notable advantages to administering dosage forms. One of the most important questions to solve is the poor solubility of most drugs which produces low bioavailability and delivery problems, a major challenge for the pharmaceutical industry. Albendazole is a benzimidazole carbamate extensively used in oral chemotherapy against intestinal parasites, due to its extended spectrum activity and low cost. Nevertheless, the main disadvantage is the poor bioavailability due to its very low solubility in water. The main objective of this study was to prepare microcrystal formulations by the bottom-up technology to increase albendazole dissolution rate, in order to enhance its antiparasitic activity. Thus, 20 novel microstructures based on chitosan, cellulose derivatives, and poloxamer as a surfactant were produced and characterized by their physicochemical properties and in vitro biological activity. To determine the significance of type and concentration of polymer, and presence or absence of surfactant in the crystals, the variables area under the curve, albendazole microcrystal solubility, and drug released (%) at 30 min were analyzed with a three-way ANOVA. This analysis indicated that the microcrystals made with hydroxyethylcellulose or chitosan appear to be the best options to optimize oral absorption of the active pharmaceutical ingredient. The in vitro evaluation of anthelmintic activity on adult forms of Trichinella spiralis identified system S10A as the most effective, of choice for testing therapeutic efficacy in vivo.

Entities:  

Keywords:  albendazole; bottom-up microcrystal; chitosan; in vitro antiparasitic assay

Mesh:

Substances:

Year:  2016        PMID: 27882479     DOI: 10.1208/s12249-016-0659-z

Source DB:  PubMed          Journal:  AAPS PharmSciTech        ISSN: 1530-9932            Impact factor:   3.246


  6 in total

1.  Synthesis and characterization of a new cyclodextrin derivative with improved properties to design oral dosage forms.

Authors:  Agustina García; Josefina Priotti; Ana Victoria Codina; María Delia Vasconi; Ariel D Quiroga; Lucila I Hinrichsen; Dario Leonardi; María Celina Lamas
Journal:  Drug Deliv Transl Res       Date:  2019-02       Impact factor: 4.617

2.  New approaches to identification and characterization of tioconazole in raw material and in pharmaceutical dosage forms.

Authors:  Natalia L Calvo; Vera A Alvarez; María C Lamas; Darío Leonardi
Journal:  J Pharm Anal       Date:  2018-11-23

3.  Synthesis and characterization of mesoporous SBA-15 and SBA-16 as carriers to improve albendazole dissolution rate.

Authors:  María Esperanza Adrover; Marisa Pedernera; Magali Bonne; Bénédicte Lebeau; Verónica Bucalá; Loreana Gallo
Journal:  Saudi Pharm J       Date:  2019-11-13       Impact factor: 4.330

Review 4.  Recent Trends in Assessment of Cellulose Derivatives in Designing Novel and Nanoparticulate-Based Drug Delivery Systems for Improvement of Oral Health.

Authors:  Khaled M Hosny; Hala M Alkhalidi; Waleed S Alharbi; Shadab Md; Amal M Sindi; Sarah A Ali; Rana B Bakhaidar; Alshaimaa M Almehmady; Eman Alfayez; Mallesh Kurakula
Journal:  Polymers (Basel)       Date:  2021-12-27       Impact factor: 4.329

5.  Potential therapeutic effect of platelet-rich plasma and albendazole on the muscular phase of experimental Trichinella spiralis infection.

Authors:  Fatma M A Eissa; Ahmed H A Eassa; Rabab S Zalat; Mohamed S Negm; Marwa A Elmallawany
Journal:  Food Waterborne Parasitol       Date:  2022-09-14

Review 6.  Cyclodextrin-Modified Nanomaterials for Drug Delivery: Classification and Advances in Controlled Release and Bioavailability.

Authors:  Daniel Andrés Real; Karen Bolaños; Josefina Priotti; Nicolás Yutronic; Marcelo J Kogan; Rodrigo Sierpe; Orlando Donoso-González
Journal:  Pharmaceutics       Date:  2021-12-10       Impact factor: 6.321

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.